Data presented in Figs. 3a and 5a show that serum exo-AnxA2 levels in breast cancer patients increases with the tumor grade progression and exo-AnxA2 expression is high in serum samples of TNBC patients, respectively. This evidence concerns the gene ANXA2 and breast cancer.